REG - Redx Pharma plc - Notice of AGM

Redx PharmaAnnouncement

16/02/2024 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240216:nRSP5053Da&default-theme=true

RNS Number : 5053D  Redx Pharma plc  16 February 2024

REDX PHARMA PLC

 

("Redx" or the "Company")

 

Notice of Annual General Meeting

 

Alderley Park, UK, 16 February 2024 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, targeted therapeutics for the treatment of fibrotic disease and
cancer today announces that its Annual General Meeting will be held at 11am on
14 March 2024 at the offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N
4BQ.

 

Following the announcement of preliminary results for the financial year ended
30 September 2023 on 15 December 2023, the Company announces that the Annual
Report and Accounts and notice of Annual General Meeting have now been posted
to shareholders. The Annual Report and Accounts and notice of Annual General
Meeting are also available to view on Redx's website at www.redxpharma.com
(http://www.redxpharma.com/) .

 

Shareholders are strongly encouraged to vote by proxy, appointing the Chair of
the meeting, using the form of proxy distributed with the notice of meeting,
to ensure their vote counts. The form of proxy is also available in the
investor resources section of the Company's website: www.redxpharma.com
(http://www.redxpharma.com/)

Completed proxies should be returned to:

 

Equiniti

Aspect House

Spencer Road

Lancing

BN99 6DA

 

and must be received by 11am on 12 March 2024 to be valid.

 

 For further information, please contact:

 Redx Pharma Plc                                                                T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 SPARK Advisory Partners (Nominated Adviser)                                    T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                                 T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                                     T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                                 T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, targeted therapeutics
for the treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to clinical
proof of concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product candidate, the
selective ROCK2 inhibitor, zelasudil (RXC007), is in development for
interstitial lung disease and is undergoing a Phase 2a trial for idiopathic
pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's
second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the
treatment of fibrostenotic Crohn's disease, is progressing towards the clinic
with a Clinical Trial Application (CTA) submitted during Q4 2023. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, being developed as
a targeted treatment for Wnt-ligand dependent cancers, is expected to report
anti-PD-1 combination Phase 2 data during the first half of 2024, following
which Redx will seek a partner for ongoing development.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its wholly-owned clinical-stage
product candidates and discovery pipeline, but also by its strategic
transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the
only non-covalent or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGPUBCPUPCGQQ